Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID ROSMARIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1730353665
CMS profile
1010770
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$267,875.61

215 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $74,281.49 53
Lilly USA, LLC $40,700.29 40
Amgen Inc. $29,797.52 23
GENZYME CORPORATION $20,494.50 9
ABBVIE INC. $17,104.13 20
Novartis Pharmaceuticals Corporation $16,996.64 11
Eli Lilly and Company $16,280.01 23
Janssen Scientific Affairs, LLC $13,143.65 8
Regeneron Healthcare Solutions, Inc. $10,672.31 8
E.R. Squibb & Sons, L.L.C. $7,405.04 6
Janssen Biotech, Inc. $7,310.03 8
PFIZER INC. $5,200.00 2
Merck Sharp & Dohme LLC $4,270.00 1
UCB, Inc. $2,360.00 2
Boehringer Ingelheim Pharmaceuticals, Inc. $1,860.00 1

Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID ROSMARIN

NPI 1730353665 · CMS profile ID 1010770

Allopathic & Osteopathic Physicians / Dermatology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID ROSMARIN, NPI 1730353665, CMS profile ID 1010770, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–215 of 215 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1730353665?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

215 matching records · $267,875.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 215 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–215 of 215.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $434.2502/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891481759 CMS
Incyte Corporation $3,155.0002/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032999 CMS
Incyte Corporation $275.0002/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943033153 CMS
Amgen Inc. $1,500.0002/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939905395 CMS
Incyte Corporation $2,800.0002/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032991 CMS
ABBVIE INC. $1,500.0002/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891481755 CMS
Incyte Corporation $4,200.0001/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032973 CMS
Incyte Corporation $2,800.0001/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032981 CMS
Incyte Corporation $433.4701/31/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943033001 CMS
PFIZER INC. $1,300.0001/28/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949591615 CMS
Incyte Corporation $133.0501/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032977 CMS
Janssen Scientific Affairs, LLC $3,575.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887217079 CMS
Incyte Corporation $107.4501/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032971 CMS
Incyte Corporation $709.5201/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032975 CMS
Janssen Scientific Affairs, LLC $1,430.0001/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887217085 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $245,142.48 315
PY2020 $147,848.56 89
PY2021 $199,480.68 130
PY2022 $267,875.61 215
PY2023 $90,074.25 74
PY2024 $92,228.49 77
PY2025 $80,711.06 50

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,690.00 11
PY2025 Principal investigator $209,432.13 33
PY2024 Recipient $1,402.08 9
PY2024 Principal investigator $169,590.19 15
PY2023 Recipient $124.95 1
PY2023 Principal investigator $107,393.84 59
PY2022 Recipient $299.00 1
PY2022 Principal investigator $343,154.51 104
PY2021 Recipient $1,641.00 1
PY2021 Principal investigator $554,925.42 105
PY2020 Recipient $4,363.00 3
PY2020 Principal investigator $679,242.21 86
PY2019 Recipient $3,146.49 3
PY2019 Principal investigator $1,247,708.88 107

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,179.12 12/31/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY HEALTH CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534095
Principal investigator 1 ABBVIE INC. $9,060.48 12/19/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202531570
Recipient PFIZER INC. $1,820.00 12/19/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810955
Recipient PFIZER INC. $3,200.00 12/19/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810961
Recipient PFIZER INC. $3,200.00 12/15/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228810968
Principal investigator 1 ABBVIE INC. $2,699.09 12/04/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527990
Principal investigator 1 Incyte Corporation $7,461.00 11/25/2025 Non-covered Recipient Entity
TRUSTEES OF INDIANA UNIVERSITY
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240604464
Principal investigator 1 Incyte Corporation $2,550.00 11/19/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1240539022
Principal investigator 1 PFIZER INC. $3,350.00 11/13/2025 Non-covered Recipient Entity
The Trustees of Indiana University
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228817523
Principal investigator 1 ABBVIE INC. $8,116.82 11/04/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202521003
Principal investigator 1 Incyte Corporation $351.90 10/28/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539069
Principal investigator 1 PFIZER INC. $25,209.60 09/24/2025 Non-covered Recipient Entity
The Trustees of Indiana University
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228836976
Principal investigator 1 Incyte Corporation $1,672.20 09/11/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539066
Principal investigator 1 ABBVIE INC. $800.00 08/21/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202505429
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 08/15/2025 Non-covered Recipient Entity
Indiana University Trustees of Indiana University
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220799868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,779.15 08/14/2025 Covered Recipient Teaching Hospital
TUFTS MEDICAL CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID No dispute reported 06/30/2026 1184137511
Principal investigator 1 CSL Behring $1,000.00 07/25/2025 Non-covered Recipient Entity
Indiana University
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252671224
Principal investigator 1 CSL Behring $1,900.00 07/25/2025 Non-covered Recipient Entity
Indiana University
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252671226
Principal investigator 1 CSL Behring $2,850.00 07/25/2025 Non-covered Recipient Entity
Indiana University
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252671228
Principal investigator 1 Incyte Corporation $351.90 07/22/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539044
Principal investigator 1 AstraZeneca UK Limited $36,390.24 07/18/2025 Non-covered Recipient Entity
TRUSTEES OF INDIANA UNIVERSITY
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185544707
Principal investigator 1 Incyte Corporation $16,800.00 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539040
Principal investigator 1 Incyte Corporation $3,400.00 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539047
Principal investigator 1 Incyte Corporation $4,600.00 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539051
Principal investigator 1 Incyte Corporation $144.00 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539055
Principal investigator 1 Incyte Corporation $7,600.00 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539059
Principal investigator 1 Incyte Corporation $12,471.68 07/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539063
Principal investigator 1 ABBVIE INC. $8,115.00 07/02/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202496551
Recipient PFIZER INC. $940.00 06/28/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839337
Principal investigator 1 ABBVIE INC. $8,944.00 06/25/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202492895
Principal investigator 1 Incyte Corporation $2,601.90 06/19/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539035
Principal investigator 1 PFIZER INC. $915.57 06/09/2025 Non-covered Recipient Entity
Indiana University Health Univ
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228814645
Recipient PFIZER INC. $940.00 06/07/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838958
Recipient PFIZER INC. $940.00 06/07/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839041
Principal investigator 1 Incyte Corporation $45.00 06/01/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539073
Recipient PFIZER INC. $330.00 05/15/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839176
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838210
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228838558
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839019
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228839477
Principal investigator 1 PFIZER INC. $3,000.00 05/03/2025 Non-covered Recipient Entity
The Trustees of Indiana University
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228857147
Principal investigator 1 Incyte Corporation $351.90 05/02/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539030
Principal investigator 1 Incyte Corporation $10,422.90 04/10/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY SCHOOL OF MEDICINE IUSM INDIANAPOLIS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240539026
Principal investigator 1 ABBVIE INC. $18,298.68 02/03/2025 Non-covered Recipient Entity
INDIANA UNIVERSITY
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202443606